{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-027171","form_type":"8-K","ticker":"PPCB","cik":"0001517681","company_name":"Propanc Biopharma, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.171187+00:00","generated_at":"2026-06-12T01:43:02.657162+00:00","sec_items":["1.01","1.02","2.03","3.02","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Propanc Biopharma issues $45K convertible note at 65% discount; terminates $5M equity line","bullets":["Issued $45,000 convertible promissory note to 1800 Diagonal Lending LLC, convertible at 65% of market price after 180 days.","8% annual interest (22% on default), maturity July 19, 2024; prepayment allowed at premiums up to 129% within 180 days.","Termination of $5,000,000 equity line agreement with an institutional investor on July 25, 2023 due to registration disagreement.","Note issued as unregistered security under Section 4(a)(2) and Regulation D; proceeds for working capital.","Company must maintain share reserve of 500% of conversion shares and avoid becoming shell company without investor consent."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-027171","json":"https://secwatch.observer/filing/0001493152-23-027171.json","markdown":"https://secwatch.observer/filing/0001493152-23-027171.md","text":"https://secwatch.observer/filing/0001493152-23-027171.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223027171/0001493152-23-027171-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223027171/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T01:43:02.657162+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8c5f39e9d88d552c422a4f4e08b54cb1ebf44c61","claim":"Propanc Biopharma, Inc. incurred convertible notes of $45,000 with an investor at 8% per annum, which may be increased to 22% in the event of a default maturing July 19, 2024.","evidence_excerpt":"On July 19, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), which closed on July 28, 2023, pursuant to which the Investor purchased a convertible promissory note (the “Note”) from the Company in the aggregate principal amount of $45,000","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223027171/0001493152-23-027171-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$45,000"},{"label":"Counterparty","value":"an investor"},{"label":"Rate","value":"8% per annum, which may be increased to 22% in the event of a default"},{"label":"Maturity","value":"July 19, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"729418028aa693914fc180f9015c6bf96de09fc9","claim":"Propanc Biopharma, Inc. terminated Equity Line Agreement (effective 2023-07-25).","evidence_excerpt":"On July 25, 2023, due to a disagreement between the parties relating to the registration of such shares of Common Stock, the Company notified such investor of the termination of the Equity Line Agreement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223027171/0001493152-23-027171-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"equity purchase"},{"label":"Effective","value":"2023-07-25"}],"fact_type":"material_agreement"},{"claim_id":"c42b2adb4239591c6cdc069eae15950154ae89f7","claim":"Propanc Biopharma, Inc. entered into Purchase Agreement valued at $45,000 (effective 2023-07-19).","evidence_excerpt":"On July 19, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), which closed on July 28, 2023, pursuant to which the Investor purchased a convertible promissory note (the “Note”) from the Company in the aggregate principal amount of $45,000","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223027171/0001493152-23-027171-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Value","value":"$45,000"},{"label":"Effective","value":"2023-07-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}